Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of lycojaponicumin A in the preparation of medicine for treating dengue virus infection
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A dengue virus and drug technology, applied in antiviral agents, pharmaceutical formulas, and resistance to vector-borne diseases, can solve the problems of no therapeutic drugs, etc., achieve good inhibitory effect, significant prevention and treatment, and highlight the effect of substantive characteristics
Inactive Publication Date: 2015-08-19
赵社良
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, there is currently no effective drug for the treatment of
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0035] Embodiment 1: the preparation of the compound Lycojaponicumin A tablet involved in the present invention:
[0036] Take 20 grams of compound Lycojaponicumin A, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tablet press.
Embodiment 2
[0037] Embodiment 2: the preparation of the compound Lycojaponicumin A capsules involved in the present invention:
[0038] Get 20 grams of compound Lycojaponicumin A, add conventional auxiliary materials such as starch 180 grams for the preparation of capsules, mix well, and pack into capsules to make 1000 tablets.
[0039] The following pharmacodynamic experiments will further illustrate its drug activity.
experiment example 1
[0041] Lycojaponicumin A is used as a (inhibition) application in the preparation of a medicine for treating or preventing dengue virus infection, and its basic process is:
[0042] Toxicity test of A.Lycojaponicumin A on Vero cells:
[0043] Vero cells (African green monkey kidney cells) are susceptible cells to DENV.
[0044] The experimental steps are as follows:
[0045] 1: Inoculate Vero cells: Use DMEM medium containing 10% (v / v) fetal bovine serum to make a single cell suspension, inoculate 1000-10000 cells per well into a 96-well cell culture plate, and inoculate a volume of 100ul per well ;
[0046] 2: Culture Vero cells: at 37°C, 5% (v / v) CO 2 Under culture conditions, cultivate for 2 days;
[0047] 3: Add Lycojaponicumin A: Discard the DMEM medium in each well, add 100ul to each well and dilute to the corresponding concentration with DMEM medium containing 10% (v / v) fetal bovine serum (0uM, 0.4uM, 1.2 uM, 3.7uM, 11uM, 33uM, 100uM, 300uM) Lycojaponicumin A, add ...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses application of Lycojaponicumin A in medicaments for treating dengue virus infection. The Lycojaponicumin A can effectively inhibit proliferation of dengue viruses, but has low toxicity to cells, can be further developed into the medicaments for treating diseases caused by the dengue virus infection, and has a wide application prospect. The application of the Lycojaponicumin A in preparation of the medicaments for treating or preventing the dengue virus infection is made public for the first time; because the skeleton type is completely novel and the Lycojaponicumin A has an unexpectedly strong dengue virus inhibiting activity, the probability that other compounds give any revelation does not exist, outstanding substantive features are provided, meanwhile, prominent improvement is evidently made in prevention and treatment of the dengue virus infection.
Description
technical field [0001] The invention belongs to the field of biomedicine, and more specifically relates to the application of Lycojaponicumin A in the preparation of medicines for treating or preventing dengue virus infection. Background technique [0002] Dengue virus (DENV) can cause dengue fever, which is transmitted by Aedes mosquitoes. Severely infected people will develop dengue hemorrhagic fever and dengue shock syndrome, and the fatality rate is extremely high. There are four serotypes of the virus, with serotype 2 being the epidemic strain. The disease is mainly endemic in tropical and subtropical countries in Southeast Asia, the Pacific region, and the Americas. China's Guangdong Province, Hainan Province, and Guangxi Province had 14 dengue fever epidemics of different scales. The main vectors of dengue fever in China are Aedes aegypti and Aedes albopictus. The former is distributed in the southern coastal areas, while the latter is widely distributed in the nor...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More